Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Lymphoid 1Gastrointestinal 1

Conditions

Vomiting 5Nausea 4Neoplasms 3Lymphoma 2Solid Tumors 1Prostatic Neoplasms 1Polyps 1Mouth Neoplasms 1Metastatic Neuroendocrine Prostate Cancer 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Intestinal Obstruction 1Hypopharyngeal Neoplasms 1Critical Illness 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

Fluorouracil 218Leucovorin 201Oxaliplatin 191Irinotecan 148Bevacizumab 107Capecitabine 93Cetuximab 89Folfox protocol 54Chemotherapy, Adjuvant 34Panitumumab 30pembrolizumab 23Nivolumab 22Colonoscopy 22Gemcitabine 20Magnetic Resonance Spectroscopy 19Floxuridine 19IFL protocol 18Celecoxib 18Radiotherapy 17Neoadjuvant Therapy 17Early Intervention, Educational 17Drug Therapy 17Laparoscopy 14Cyclophosphamide 14Counseling 14trifluridine tipiracil drug combination 13regorafenib 13XELOX 13Exercise 13Erlotinib Hydrochloride 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Colonic Neoplasms × Metoclopramide × Clear all
NCT01851369 2024-05-08

TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
93 enrolled 27 charts
GastrointestinalLymphoid

Colonic Neoplasms, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡